+Vote!
Business Wire (Free subscription) | 24/11/2009
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 9:30 a.m. ET at the New York Palace in New York, NY. A live webcast of the presentation can be accessed under “Calendar of Events” in the...
3Vote!
Business Wire (Free subscription) | 16/11/2009
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the upcoming Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 3:10 p.m. ET at the St. Regis Hotel in New York, NY. A live webcast of the presentation can be accessed under “Calendar of Events”...
3Vote!
Business Wire (Free subscription) | 10/11/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE: ACL), Novartis (NYSE: NVS), Gilead Sciences (Nasdaq: GILD), Biogen Idec (Nasdaq: BIIB) and Acorda Therapeutics (Nasdaq: ACOR). A synopsis of today’s Industry Outlook is presented below. The full article can be read...
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 12/11/2009
Explore : Alcon,
Biogen Idec,
Biotechnologies,
Business Services,
Drug Manufacturers,
Health Industries,
Medical Products and Supplies,
Money,
NASDAQ,
Novartis,
Stock exchange
3Vote!
The Earth Times Online Newspaper (Free subscription) | 10/11/2009
CHICAGO - Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE:
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 12/11/2009
3Vote!
Business Wire (Free subscription) | 06/11/2009
CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Acorda Therapeutics (Nasdaq: ACOR) as the Bull of the Day and Canon (NYSE: CAJ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Big Lots (NYSE: BIG), Wal-Mart (NYSE: WMT) and Nordstrom (NYSE: JWN). Full analysis of all these stocks is available at http://at.zacks.com/?id=2678. Here is a synopsis of all five...
Explore : Apparel Stores,
Big Lots,
Business Services,
Discount Stores,
Money,
NASDAQ,
New York Stock Exchange,
Nordstrom,
Retail,
Stock exchange,
Wal-Mart
3Vote!
GuruFocus Updates (Free subscription) | 06/11/2009
By 10qk. Acorda Therapeutics Inc. ( ACOR ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
3Vote!
Business Wire (Free subscription) | 03/11/2009
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the third quarter of 2009. “The positive vote from the FDA Advisory Committee was an important step toward making Fampridine-SR available to people with multiple sclerosis who may benefit from this novel therapy, if approved,” said Ron Cohen, M.D., Acorda Therapeutics’...
+Vote!
Business Wire (Free subscription) | 27/10/2009
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that it will host a conference call and live audio webcast to report its financial results for the third quarter 2009 on Tuesday, November 3, 2009 at 8:30 a.m. ET before the U.S. financial markets open. To participate in the conference call, please dial 800-561-2718 (domestic) or 617-614-3525 (international)...
3Vote!
Business Wire (Free subscription) | 22/10/2009
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its review of the New Drug Application (NDA) for Fampridine-SR to January 22, 2010. The original Prescription Drug User Fee Act (PDUFA) date for this priority review application was October 22, 2009. Following the Peripheral...
3Vote!
Business Wire (Free subscription) | 14/10/2009
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that NASDAQ has halted trading of Acorda common stock. The U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meets today to review and discuss Acorda’s New Drug Application (NDA) for Fampridine-SR for improvement of walking ability in people...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 15/10/2009
Acorda Therapeutics (NGM: ACOR) opened at $25.24. So far today, the stock has hit a low of $24.58 and a high of $26.00. ACOR is now trading at $24.65, up $7.91 (47.25%). Over the last 52 weeks the stock has ranged from a low of $14.42 to a high of $29.27. ACOR shares are rising rapidly today after an FDA panel released a positive review of Acorda's multiple sclerosis drug candidate Fampridine-SR....
3Vote!
iStockAnalyst.com (Free subscription) | 15/10/2009
On 4/23/09, Acorda Therapeutics (NASDAQ: ACOR) announced the resubmission of its NDA for Fampridine-SR (Amaya) to the FDA as a new therapy being developed to improve walking ability in people with multiple sclerosis (MS) in response to a Refuse to File letter for the NDA issued by the Agency in late March. On 5/6/09, the FDA accepted the NDA with a priority review (six-month review) designation...
